Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Early Stage Non-Small Cell Lung Cancer cancer Non-Small Cell Lung Cancer SBRT Avelumab Stereotactic Body Radiation Therapy radiation NSCLC PD-1 PD-L1 Immunotherapy Lung Lung Neoplasms Carcinoma, Non-Small-Cell Lung Antibodies, Monoclonal SBRT+Avelumab
Lead Scientist at UCSD
- Andrew Sharabi, M.D., Ph.D.
Dr. Andrew Sharabi is a physician scientist and board-certified radiation oncologist at UC San Diego Moores Cancer Center. He sees patients at the La Jolla Moores Cancer Center and his specialties include Prostate (Genitourinary) and Head and Neck Cancers, as well as Skin Cancer and Thoracic Malignancies.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Andrew Sharabi
- Phase 1/2
- Study Type
- Last Updated